Wockhardt Limited
WOCKPHARMA
Classement en actions
#4552
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Prix de l'action
$20.75
Capitalisation boursière
$3.37B
Changement (1 jour)
-1.38%
Changement (1 an)
33.03%
Pays
IN
Échange Wockhardt Limited (WOCKPHARMA)
Catégorie
Healthcare
Revenus pour Wockhardt Limited (WOCKPHARMA)
Revenus en Jun 2026 TTM : $393.32M
Selon les derniers rapports financiers de Wockhardt Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de $393.32M. En 2024, l'entreprise a réalisé un chiffre d'affaires de $339.40M une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $323.31M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Wockhardt Limited de 2004 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $393.32M | 10.84% |
| 2025 | $354.86M | 4.56% |
| 2024 | $339.40M | 4.97% |
| 2023 | $323.31M | -24.02% |
| 2022 | $425.51M | 15.02% |
| 2021 | $369.93M | -2.01% |
| 2020 | $377.51M | -26.48% |
| 2019 | $513.51M | -14.80% |
| 2018 | $602.74M | -1.45% |
| 2017 | $611.63M | -9.01% |
| 2016 | $672.19M | -6.41% |
| 2015 | $718.21M | -10.88% |
| 2014 | $805.87M | -22.17% |
| 2013 | $1.04B | 13.80% |
| 2012 | $909.89M | 8.10% |
| 2011 | $841.74M | -16.02% |
| 2010 | $1.00B | 35.33% |
| 2008 | $740.59M | 9.85% |
| 2007 | $674.18M | 72.85% |
| 2006 | $390.03M | 24.39% |
| 2005 | $313.56M | 9.96% |
| 2004 | $285.15M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $2.54B | 544.77% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | 111.23% |
US
|
|
| - | - |
IT
|
